- Home
- SMTK vs GTBP Comparison
SMTK vs GTBP Comparison
Compare SMTK & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- GTBP
- Stock Information
- Founded
- SMTK 2009
- GTBP 1965
- Country
- SMTK United Kingdom
- GTBP United States
- Employees
- SMTK N/A
- GTBP N/A
- Industry
- SMTK
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- SMTK
- GTBP Health Care
- Exchange
- SMTK NYSE
- GTBP Nasdaq
- Market Cap
- SMTK 6.1M
- GTBP 5.5M
- IPO Year
- SMTK N/A
- GTBP N/A
- Fundamental
- Price
- SMTK $0.93
- GTBP $3.48
- Analyst Decision
- SMTK
- GTBP Strong Buy
- Analyst Count
- SMTK 0
- GTBP 1
- Target Price
- SMTK N/A
- GTBP $11.00
- AVG Volume (30 Days)
- SMTK 150.8K
- GTBP 75.0K
- Earning Date
- SMTK 08-11-2025
- GTBP 08-13-2025
- Dividend Yield
- SMTK N/A
- GTBP N/A
- EPS Growth
- SMTK N/A
- GTBP N/A
- EPS
- SMTK N/A
- GTBP N/A
- Revenue
- SMTK $105,000.00
- GTBP N/A
- Revenue This Year
- SMTK N/A
- GTBP N/A
- Revenue Next Year
- SMTK N/A
- GTBP N/A
- P/E Ratio
- SMTK N/A
- GTBP N/A
- Revenue Growth
- SMTK 854.54
- GTBP N/A
- 52 Week Low
- SMTK $0.78
- GTBP $1.72
- 52 Week High
- SMTK $7.80
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- GTBP 76.91
- Support Level
- SMTK N/A
- GTBP $2.75
- Resistance Level
- SMTK N/A
- GTBP $3.28
- Average True Range (ATR)
- SMTK 0.00
- GTBP 0.26
- MACD
- SMTK 0.00
- GTBP 0.07
- Stochastic Oscillator
- SMTK 0.00
- GTBP 96.72
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in several applications, including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.